Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trametinib - Novartis

Drug Profile

Trametinib - Novartis

Alternative Names: 1120212; GSK-1120212; GSK-1120212B; JTP-74057; Mecinist; Mekinist; Mekinisuto; TMT 212; Trametinib dimethyl sulfoxide; Trametinib DMSO

Latest Information Update: 14 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Japan Tobacco
  • Developer Amgen; Dana-Farber Cancer Institute; GlaxoSmithKline; Japan Tobacco; M. D. Anderson Cancer Center; Merck Sharp & Dohme; National Cancer Institute (USA); Novartis; Pfizer; University of Texas M. D. Anderson Cancer Center
  • Class 2 ring heterocyclic compounds; Amides; Antineoplastics; Cyclopropanes; Fluorobenzenes; Iodobenzenes; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Thyroid cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma; Non-small cell lung cancer
  • Registered Thyroid cancer
  • Phase II Acute myeloid leukaemia; Biliary cancer; Brain metastases; Breast cancer; Cancer; Cervical cancer; Colorectal cancer; Endometrial cancer; Glioma; Multiple myeloma; Myeloid leukaemia; Pancreatic cancer; Uveal melanoma
  • Phase I/II Solid tumours
  • No development reported Leukaemia; Lymphoma; Mesothelioma
  • Discontinued Inflammation

Most Recent Events

  • 12 Jan 2019 National Cancer Institute plans a phase II trial for Erdheim Chester disease (PO) (NCT03794297)
  • 01 Dec 2018 Updated efficacy and adverse events data from the phase II ROAR trial in Hairy cell leukaemia were presented at the 60th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2018)
  • 13 Nov 2018 Updated efficacy and adverse events data from a phase II trial in Solid tumours presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top